Aim: A new simple and sensitive high-Performance Liquid Chromatography (HPLC) method
for the determination of a potent synthetic cannabinoid THJ-2201, has been developed and validated.
Lixiviptan was used as the Internal Standard (IS).
Methods: THJ-2201 and IS were extracted from mouse plasma using deproteinization procedure that
uses acetonitrile followed by HPLC analysis. The separation was carried out on a reversed-phase C18
column using water and acetonitrile mixture (30:70 v/v). The flow-rate was 1.0 mL/min. Eluting of both
THJ-2201 and lixivaptan was performed at 220 nm.
Results: The method demonstrated linearity over a calibration range of 95 - 1500 ng/mL and the Limit
of Detection (LOD) and Quantitation (LOQ) were 28 ng/mL and 91 ng/mL, respectively. The validation
of the proposed method was carried out by following the US Food and Drug Administration (FDA)
guidelines. Intra- and inter-day precision did not exceed 6.4%, whereas the accuracy of THJ-2201
measurements was within ±13%.
Conclusion: This new method is simple and sensitive and has been applied successfully in a pharmacokinetic
study of THJ-2201 in mouse plasma. The mean values of Tmax and Cmax were 0.25 h and
141.87 ± 12.11 ng/mL, respectively.